Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25763724 | 0.85 | CYP1A2 (0.47) | RAB9ANPC1TP53NPSR1SMN1; SMN2 | |
| SCHEMBL25959755 | 0.83 | NPSR1 (0.43) | EGLN1RAB9ANPC1NPSR1SMN1; SMN2 | |
| SCHEMBL11994377 | 0.83 | HDAC3 (0.42) | EGLN1RAB9ANPC1TP53NOTUM | |
| SCHEMBL888947 | 0.81 | FTO (0.41) | RAB9ANPC1TP53KDM4EMAPT | |
| SCHEMBL12869440 | 0.81 | MAPT (0.47) | EGLN1RAB9ANPC1TP53NOTUM | |
| SCHEMBL14087358 | 0.80 | RAB9A (0.54) | RAB9ANPC1NOTUMSMN1; SMN2KDM4E | |
| SCHEMBL21937417 | 0.78 | MAPT (0.48) | NOTUMFLT1SMN1; SMN2KIF11MAPT | |
| SCHEMBL197335 | 0.78 | KIF11 (0.52) | RAB9ANPC1TP53NOTUMNPSR1 | |
| SCHEMBL12925912 | 0.78 | FTO (0.47) | EGLN1RAB9ANPC1TP53NOTUM | |
| SCHEMBL15871270 | 0.78 | CYP11B1 (0.41) | EGLN1RAB9ANPC1VEGFAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759332-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-7425281-B2 | Liquid crystal compositions comprising an organogermanium compound and methods for using the same | DISPLAYTECH, INC. (US) | 2008-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | EGLN1 2374/4885RAB9A 3060/4885NPC1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.